Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 16, Pages 4353-4358
Publisher
American Society of Hematology
Online
2011-08-17
DOI
10.1182/blood-2011-06-362889
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia
- (2010) Mariana Serpa et al. ACTA HAEMATOLOGICA
- Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning
- (2010) N. S. Majhail et al. BLOOD
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
- (2010) H. M. Kantarjian et al. BLOOD
- Uncommon case of chronic myeloid leukemia with multiple myeloma
- (2010) Masaru Ide et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling
- (2010) J. Chen et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Imatinib for refractory chronic graft-versus-host disease with fibrotic features
- (2009) A. Olivieri et al. BLOOD
- Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
- (2009) G. Rosti et al. BLOOD
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature
- (2009) Salvatore Guastafierro et al. LEUKEMIA RESEARCH
- Solid cancers after allogeneic hematopoietic cell transplantation
- (2008) J. D. Rizzo et al. BLOOD
- Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update
- (2008) R. Seggewiss et al. CYTOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started